Response of patients with secretory multiple myeloma to bortezomib and PegLD. The serum monoclonal protein level of all 19 patients with secretory multiple myeloma who were evaluable for a response is shown both at baseline and after every 2 cycles of therapy with bortezomib and PegLD. Out of the total of 22 evaluable patients, 2 with light chain only disease and 1 with nonsecretory disease are excluded from this graph. Also, 2 of these patients received a total of 11 cycles but then withdrew when bortezomib was approved by the Food and Drug Administration to receive additional treatment with their primary oncologist, and their results are shown only through cycle 10.